Anti-angiogenic effects of trabectedin (Yondelis; ET-743) on human breast cancer cells

European Cytokine Network

Volumn 25, Issue 1, 2014, Pages 1-7

  Atmaca, Harika ^a   Uzunoglu, Selim ^a  

^a CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

Angiogenic cytokines; Breast cancer cells; ET 743); HUVECs; Trabectedin (Yondelis; VEGF

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SERINE PROTEINASE INHIBITOR; SERPIN E1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRABECTEDIN; UNCLASSIFIED DRUG; VASCULOTROPIN; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; SOMATOMEDIN BINDING PROTEIN 2; TETRAHYDROISOQUINOLINE DERIVATIVE; TIMP1 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANGIOGENESIS ANTIBODY ARRAY; ANTIANGIOGENIC ACTIVITY; ARTICLE; ASSAY; BREAST CANCER; CANCER CELL; CARCINOGENICITY; CELL MIGRATION; CELL VIABILITY ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONCENTRATION; HUMAN; HUMAN CELL; IC 50; IC10; POLYMERASE CHAIN REACTION; PROTEIN MICROARRAY; REAL TIME POLYMERASE CHAIN REACTION; SCRATCH ASSAY; XTT ASSAY; BIOSYNTHESIS; BREAST NEOPLASMS; CELL MOTION; CELL SURVIVAL; DRUG EFFECTS; FEMALE; GENETICS; MCF 7 CELL LINE; NEOVASCULARIZATION (PATHOLOGY); TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, ALKYLATING; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DIOXOLES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; MCF-7 CELLS; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA, MESSENGER; TETRAHYDROISOQUINOLINES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84904467233     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2014.0347     Document Type: Article

References (31)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182.
2. Filho AL, Lopes JM, Schmitt FC. Angiogenesis and Breast Cancer. J Oncol 2010: 576384.
3. Fayette J, Soria JC, Armand JP. Use of angiogenesis inhibitors in tumour treatment. Eur J Cancer 2005; 41: 1109.
4. Giavazzi R, Taraboletti G. Angiogenesis and angiogenesis inhibitors in cancer. Forum (Genova) 1999; 9: 261.
5. Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 2004; 31: 2.
6. El Sayed KA. Natural products as angiogenesis modulators. Mini Rev Med Chem 2005; 5: 971.
7. Prat A, Casado E, Cortés J. New approaches in angiogenic targeting for colorectal cancer. World J Gastroenterol 2007; 13: 5857.
8. Valoti G, Nicoletti MI, Pellegrino A, Jimeno J, Hendriks H, D'Incalci M, Faircloth G, Giavazzi R. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res 1998; 4: 1977.
9. D'Incalci M, Galmarini CM. A Review of trabectedin (ET-743): A Unique Mechanism of Action. Mol Cancer Ther 2010; 9: 2157.
10. Atmaca H, Bozkurt E, Uzunoglu S, Uslu R, Karaca B. A diverse induction of apoptosis by trabectedin in MCF-7 (HER2-/ER+) and MDA-MB-453 (HER2+/ER-) breast cancer cells. Toxicol Lett 2013; 221: 128.
11. Kisim A, Atmaca H, Cakar B, Karabulut B, Sezgin C, Uzunoglu S, Uslu R, Karaca B. Pretreatment withAT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels. J Cancer Res Clin Oncol 2012; 138: 1155.
12. Atmaca H, Gorumlu G, Karaca B, Degirmenci M, Tunali D, Cirak Y, Purcu DU, Uzunoglu S, Karabulut B, Sanli UA, Uslu R. Combined gossypol and zoledronic acid treatment results in synergistic induction of cell death and regulates angiogenic molecules in ovarian cancer cells. Eur Cytokine Netw 2009; 20: 121.
13. Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007; 2: 329.
14. Desantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014; 64: 52.
15. Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, Gronchi A, Virdis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D'Incalci M, Allavena P. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 2010; 70: 2235.
16. Ulisse S, Baldini E, Sorrenti S, D'Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 2009; 9: 32.
17. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 Interactions and Signaling: a Vascular Biologist's View. Thromb Haemost 2007; 97: 336.
18. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991; 78: 2791.
19. Obermueller E, Vosseler S, Fusenig NE, Mueller MM. Cooperative autocrine and paracrine functions of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the progression of skin carcinoma cells. Cancer Res 2004; 64: 7801.
20. Braun B, Lange M, Oeckler R, Mueller MM. Expression of G-CSF andGM-CSFin human meningiomas correlates with increased tumor proliferation and vascularization. J Neurooncol 2004; 68: 131.
21. Bretscher V, Andreutti D, Neuville P, Martin M, Martin F, Lefebvre O, Gilles C, Benzonana G, Gabbiani G, GM-CSF G. expression by tumor cells correlates with aggressivity and with stroma reaction formation. J Submicrosc Cytol Pathol 2000; 32: 525.
22. Mueller MM, Herold-Mende CC, Riede D, Lange M, Steiner HH, Fusenig NE. Autocrine growth regulation by granulocyte colonystimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression. Am J Pathol 1999; 155: 1557.
23. Mueller MM, Fusenig NE. Constitutive expression of G-CSF and GM-CSFin human skin carcinoma cells with functional consequence for tumor progression. Int J Cancer 1999; 83: 780.
24. Pei XH, Nakanishi Y, Takayama K, Bai F, Hara N. Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells. Br J Cancer 1999; 79: 40.
25. Mueller MM, Peter W, Mappes M, et al. Tumor progression of skin carcinoma cells in vivo promoted by clonal selection, mutagenesis, and autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Am J Pathol 2001; 159: 1567.
26. Firth SM, Baxter RC. Cellular actions of the insulinlike growth factor binding proteins. Endocr Rev 2002; 23: 824.
27. Busund LT, Richardsen E, Busund R, Ukkonen T, Bjørnsen T, Busch C, Stalsberg H. Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol 2005; 58: 361.
28. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28: 20.
29. Hornebeck W, Lambert E, Petitfrère E, Bernard P. Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression. Biochimie 2005; 87: 377.
30. Heer K, Kumar H, Read JR, Fox JN, Monson JR, Kerin MJ. Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin Cancer Res 2001; 7: 3491.
31. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273.